Tempus Reports Third Quarter 2026 Results
Key Highlights
- ➤Q3 revenue $411.5 million, up 23% year over year
- ➤Adjusted EBITDA $25.6 million, versus $1.5 million in Q3 2025
- ➤2026 revenue guidance raised to $1.60-$1.605 billion; Adjusted EBITDA ~$65 million
- ➤BMS licensing deal totals up to $137.5 million over five years
- ➤Personalis (PSNL) acquisition cleared regulatory review; shareholder vote planned November 30
Expert Statements
Eric Lefkofsky, Founder and CEO of Tempus
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications”
Eric Lefkofsky, Founder and CEO of Tempus
“These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky, founder and CEO of Tempus. “These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
Get started
Create a free account to read the full story.